A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Previous clinical studies showed there is a potential value of EGFR-TKI in local advanced
EGFR-mutant NSCLC, while the risk of radiation pneumonia in combination of EGFR-TKI with
thoracic radiotherapy is unknown. This study aims to explore the safety and efficacy of
concurrent almonertinib, a new third-generation EGFR-TKI drug, with radiotherapy in local
advanced EGFR-mutant NSCLC patients.